In June 2025, the 85th American Diabetes Association (ADA) Scientific Sessions concluded successfully in Chicago, USA. As a premier global scientific gathering in the field of diabetes, the ADA Scientific Sessions brought together leading experts, researchers, and healthcare professionals worldwide. During the conference, Gan & Lee Pharmaceuticals highlighted the latest R&D progress and data for its innovative drug candidates, the GLP-1 receptor agonist Bofanglutide and the once-weekly basal insulin GZR4. The company also presented an overview of its overseas R&D pipeline, showcasing Gan & Lee's innovative breakthroughs and commitment to global development to international experts and the patient community.